Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data

Reuters03-18 20:04

Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data

Alumis said 24-week results from the Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib (ESK-001), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver. The oral presentation is scheduled for March 28, 2026, at 11:12 am MDT at Bellco Theatre 3. Alumis also said a subgroup analysis from the Phase 2 STRIDE trial on proteomic and transcriptomic tape-strip biomarkers will be presented as an e-poster (poster 73714) at the same meeting. The company plans to post the presentations on its website on March 28, 2026, in line with the meeting’s embargo policy. Alumis also scheduled an investor webcast on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674189) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620253326?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620253326","market":"us","top_or_hot":-1,"title":"Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis said 24-week results from the Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib (ESK-001), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver. The oral presentation is scheduled for March 28, 2026, at 11:12 am MDT at Bellco Theatre 3. Alumis also said a subgroup analysis from the Phase 2 STRIDE trial on proteomic and transcriptomic tape-strip biomarkers will be presented as an e-poster (poster 73714) at the same meeting. The company plans to post the presentations on its website on March 28, 2026, in line with the meeting’s embargo policy. Alumis also scheduled an investor webcast on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674189) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alumis said 24-week results from the Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib (ESK-001), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver. The oral presentation is scheduled for March 28, 2026, at 11:12 am MDT at Bellco Theatre 3. Alumis also said a subgroup analysis from the Phase 2 STRIDE trial on proteomic and transcriptomic tape-strip biomarkers will be presented as an e-poster (poster 73714) at the same meeting. The company plans to post the presentations on its website on March 28, 2026, in line with the meeting’s embargo policy. Alumis also scheduled an investor webcast on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/ALMS\">Alumis Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674189) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDLftG8V:1","article_id":"2620253326","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620253326","pubTimestamp":1773835487,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alumis said 24-week results from the Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib , an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver. The oral presentation is scheduled for March 28, 2026, at 11:12 am MDT at Bellco Theatre 3. Alumis also said a subgroup analysis from the Phase 2 STRIDE trial on proteomic and transcriptomic tape-strip biomarkers will be presented as an e-poster  at the same meeting. The company plans to post the presentations on its website on March 28, 2026, in line with the meeting’s embargo policy. Alumis also scheduled an investor webcast on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","NDAQ":"纳斯达克OMX交易所","BK4585":"ETF&股票定投概念","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","ALMS":"Alumis Inc.","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4588":"碎股","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4112":"金融交易所和数据","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Alumis在AAD 2026上发布了最新的3期ONWARD1和ONWARD2 envudeucitinib银屑病数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ALMS":0.9},"content_text":"Alumis sets late-breaking AAD 2026 oral presentation of Phase 3 ONWARD1 and ONWARD2 envudeucitinib psoriasis data\n    \n\n        Alumis said 24-week results from the Phase 3 ONWARD1 and ONWARD2 trials of envudeucitinib (ESK-001), an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, will be presented as a late-breaking oral session at the 2026 American Academy of Dermatology Annual Meeting in Denver. The oral presentation is scheduled for March 28, 2026, at 11:12 am MDT at Bellco Theatre 3. Alumis also said a subgroup analysis from the Phase 2 STRIDE trial on proteomic and transcriptomic tape-strip biomarkers will be presented as an e-poster (poster 73714) at the same meeting. The company plans to post the presentations on its website on March 28, 2026, in line with the meeting’s embargo policy. Alumis also scheduled an investor webcast on March 29, 2026, at 5:00 pm MDT to review the Phase 3 ONWARD data.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674189) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620253326","isCrawlerRequest":true}